ArticleProceedings of the National Academy of Sciences of the United States of America2023
Inhibition of
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
10.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease.Circulation research · 2026Review
- Membrane bridges and nanodomain partitioning govern membrane protein targeting to lipid droplets.Nature cell biology · 2026Article
- Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD): a growing health concern in the age of childhood obesity.BMJ paediatrics open · 2026Review
- Disease-driven loss of inactive HSD17B13 isoforms enhances enzymatic output in MASH and counters protective rs72613567:TA variant.JHEP reports : innovation in hepatology · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach.The Kaohsiung journal of medical sciences · 2026Review
- Drug Repurposing for Metabolic-Associated Fatty Liver Disease: Current Evidence, Challenges, and Future Perspectives.Drug design, development and therapy · 2026Review
- Mitochondrial dysfunction and lipid droplet dynamics in MASH: HSD17B13 as a therapeutic target.Frontiers in cell and developmental biology · 2026Review
- Phenotypic Screening Coupled with AI-Driven Target Deconvolution Identifies α-Terthienyl as a Dual DPP-IV/HSD17β13 Modulator with Efficacy in a Mouse Model of MASLD.bioRxiv : the preprint server for biology · 2025Article
- Hydroxysteroid 17β-dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high-fat diet obese mice.Experimental physiology · 2025Article
- Single-cell eQTL analysis identifies genetic variation underlying metabolic dysfunction-associated steatohepatitis.Nature genetics · 2025Article
- Lipidomic Profiling Reveals HSD17B13 Deficiency-Associated Dysregulated Hepatic Phospholipid Metabolism in Aged Mice.Metabolites · 2025Article
- Human menstrual blood-derived stem cells secreted ECM1 directly interacts with LRP1α to ameliorate hepatic fibrosis through FoxO1 and mTOR signaling pathway.Stem cell research & therapy · 2025Article
- LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology.Seminars in liver disease · 2025Review
- Mass spectrometry imaging reveals spatial metabolic variation and the crucial role of uridine metabolism in liver injury caused by Schistosoma japonicum.PLoS neglected tropical diseases · 2025Article
- Design and application of synthetic 17B-HSD13 substrates reveals preserved catalytic activity of protective human variants.Nature communications · 2025Article
- MASH and the race for liver antifibrotics.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025Article
- Integrated serum metabolomics and network pharmacology reveal molecular mechanism of Qixue Huazheng formula on peritoneal fibrosis.Frontiers in pharmacology · 2025Article
- Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease.Frontiers in physiology · 2025Review
- Metabolomics at the cutting edge of risk prediction of MASLD.Cell reports. Medicine · 2024Review
- Rab2A-mediated Golgi-lipid droplet interactions support very-low-density lipoprotein secretion in hepatocytes.The EMBO journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 3 countries.
Panu K LuukkonenDepartment of Internal Medicine, Yale School of Medicine, New Haven 06520, CT.ORCID 0000-0003-2085-679X
Ikki SakumaDepartment of Internal Medicine, Yale School of Medicine, New Haven 06520, CT.
Rafael C GasparDepartment of Internal Medicine, Yale School of Medicine, New Haven 06520, CT.
Meghan MooringDepartment of Pediatrics, The Yale Liver Center, Yale School of Medicine, New Haven 06520, CT.
Ali NasiriDepartment of Internal Medicine, Yale School of Medicine, New Haven 06520, CT.
Mario KahnDepartment of Internal Medicine, Yale School of Medicine, New Haven 06520, CT.
Xian-Man ZhangDepartment of Internal Medicine, Yale School of Medicine, New Haven 06520, CT.
Dongyan ZhangDepartment of Internal Medicine, Yale School of Medicine, New Haven 06520, CT.ORCID 0000-0002-4036-3987
Henna SammalkorpiDepartment of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Helsinki 00290, Finland.
Anne K PenttiläDepartment of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Helsinki 00290, Finland.
Marju Orho-MelanderDepartment of Clinical Sciences, Diabetes and Endocrinology, University Hospital Malmö, Lund University, Malmö 21428, Sweden.
Johanna ArolaDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki 00290, Finland.
Anne JuutiDepartment of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Helsinki 00290, Finland.
Xuchen ZhangDepartment of Pathology, Yale School of Medicine, New Haven 06520, CT.
Dean YimlamaiDepartment of Pediatrics, The Yale Liver Center, Yale School of Medicine, New Haven 06520, CT.
Hannele Yki-JärvinenMinerva Foundation Institute for Medical Research, Helsinki 00290, Finland.
Kitt Falk PetersenDepartment of Internal Medicine, Yale School of Medicine, New Haven 06520, CT.ORCID 0000-0003-2664-670X
Gerald I ShulmanDepartment of Internal Medicine, Yale School of Medicine, New Haven 06520, CT.ORCID 0000-0003-1529-5668
Yale University · USUniversity of Helsinki · FIYale Cancer Center · USLund University · SE
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MSPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5MYale Diabetes Research CenterP30DK045735 · NIDDK · YALE UNIVERSITY · PI GERALD I SHULMAN · 1993 to 2026
$44.0MYale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI WAJAHAT Zafar MEHAL · 1986 to 2026
$31.1MCellular Approaches to Tissue Engineering/RegenerationT32EB001026 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DUNCAN, ANDREW W, MONGA, SATDARSHAN SINGH · 2003 to 2024
$5.5MEffects of Hepatic Acetyl-CoA Carboxylase Inhibition on NAFLD and Hepatic Insulin ResistanceR01DK113984 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2017 to 2021
$3.7MDevelopment of Controlled Release Mitochondrial Protonophore (CRMP) as a Novel Treatment for Type-2 Diabetes and Non-Alcoholic Steatohepatitis in Dysmetabolic Non-Human PrimatesR01DK119968 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2019 to 2024
$2.7MDeciphering Epithelial Signals in the Liver to Drive Inflammation and FibrosisR01DK129552 · NIDDK · YALE UNIVERSITY · PI YIMLAMAI, DEAN · 2021 to 2025
$2.2MTargeting hepatic mitochondrial oxidation to treat NAFLD, NASH and type 2 diabetesR01DK135645 · NIDDK · YALE UNIVERSITY · PI KITT F PETERSEN, GERALD I SHULMAN · 2024 to 2026
$2.1MBETA-CATENIN AS A THERAPEUTIC TARGET IN HEPATOCELLULAR CANCERR01CA124414 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MONGA, SATDARSHAN SINGH · 2007 to 2011
$1.3MHepatocyte Hippo Signaling Drives Inflammation in Liver Injury and RegenerationR03DK124743 · NIDDK · YALE UNIVERSITY · PI YIMLAMAI, DEAN · 2020 to 2021
$251kNCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA124414NIBIB NIH HHS T32 EB001026NIDDK NIH HHS P30 DK034989NIDDK NIH HHS P30 DK036836NIDDK NIH HHS P30 DK045735NIDDK NIH HHS R01 DK113984NIDDK NIH HHS R01 DK119968NIDDK NIH HHS R01 DK129552NIDDK NIH HHS R01 DK135645NIDDK NIH HHS R03 DK124743
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, in which prognosis is determined by liver fibrosis. A common variant in hydroxysteroid 17-beta dehydrogenase 13 (
Indexed as
Non-alcoholic Fatty Liver Disease17-Hydroxysteroid DehydrogenasesAnimalsHumansLiverLiver CirrhosisMicePyrimidines17-Hydroxysteroid DehydrogenasesHSD17B13 protein, humanpyrimidinePyrimidineshydroxysteroid 17-beta dehydrogenase 13liver fibrosisnonalcoholic fatty liver diseasenonalcoholic steatohepatitispyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.